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days, The four ascending dose groups of hirudin (recombi-
nant demdfatohimdin [CGP 39393] Cba-Geigy) were as
follows
: 0.15-mglkg body weight intravenous bolus . followed
by a 0.05-mg/kg per h fixed infusion : 0.1-nlglkg bolus fol-
lowed by a 0
.1-mg/kg per h fixed infusion ; 0.3-ragikg bolus
followed by a 0.1-mg/kg per h fixed infusion
; and 0.6mglkg
bolus followed by a 0.2-mg/kg per h fixed infusion . The
hirudin infusion was not adjusted on the basis of activated
partial rhmmboplastin time
; however, as a safety measure . if
an activated partial thrumboplastin time after 24 h was
>150 s. the infusion rate was halved
. Heparin (Liquaemin .
Organon Inc .) was administered as a 5
.000-IU intravenous
bolus followed by a 1 .000-IU7h infusion that was then
adjusted to maintain an activated partial thromboplastin time
between 65 and 90 a on the Ciba-Corning Biolrack 512
coagulation monitor(Ciba-Corning Diagnostics Corporation)
according to a standardized nomogram adapted from Hirsh
(16). Blood samples were obtained for activated partial
thromboplastin time measurements at baseline and 6 . 12 and
24 h after the start of thrombolytic therapy and every 12 h
thereafter while patients remained on study drug . Repeat
measurements of activated partial thmmhoplauin time were
obtained 4 to 6 h after adjustments in the heparin infusion .
The hirudin or heparin infusion was continued for 5 days
unless the patient experienced major hemorrhage . reinfarc-
tien or severe recurrent ischemia requiring angioplasty or
coronary bypass surgery .
AN patients received front-loaded t-PA (Activase, Genen-
tech) with a 15-mg bolus . 0.75-mg/kg (up to 50 mg) infusion
over 30 min, followed by a 0.50-mg/kg (up to 35 mg) infusion
over 60 min (I7) and aspirin (160 mg) chewed immediately on
emoUmeat, ff patients were not already taking aspirin . and
160 mg daily thereafter. Patients also received intravenous .
followed by Dual metoproktl tar-time (Lupressor. Cba-Geigy)
if there were no eontnsindieations (bradycarda, hypoten-
a ms, ntrloventd, Jar block or bronchospasdc lung disease)
(181. Nitrates, calcium antagonists and other medications
were administered at the discretion of the treating physician.
Patients underwent coronary artedography to ascertain
mfaret-related artery potency at 90 min after the start of
dumb** therapy . The arterial sheath for the catheter-
ization was secured in place, and repeat coronary arteriog-
raphy was performed 18 to 36 h after the am of thrombo-
lytio therapy (or earlier if the patient experienced recurrent
ischmic pain with ST segment elevation) . If the infarct-
relafed artery was occluded at 90 min (TIMI grade 0 or I
Row) (1). and after coronary occlusion was confirmed at
120 min, rescue coronary angioplasty could be performed at
the discretion of the treating physician. If angioplasty was
performed, the study drug (hirudin or study-supplied hepa-
rin) was discontinued, and further anticoagulation with hep-
ada was determined by the treating physician. Coronary
arteriography at 18 to 36 h was not required if the patient
underwent rescue angioplasty . Revasculadzation with an-
gioplasty, or coronary artery bypass surgery was recom-
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mended only if significant recurrent isehemia developed and
was performed at the discretion of the treating physician
(18) . Coronary perfusion was evaluated according to the
TIM] perfusion grading system (1) by investigators at the
angiographic core laboratory who were unaware of treat-
ment assignment.
During the hospital period, patients were monitored for
recurrent ischendc pain lasting m30 min, for which serial
ECGs and creaine kings . (CK) isoenzynies were obtained
during the subsequent 24 h
n document reinfarction. The
ECGs and enzyme measurem, nts were submitted with a
narrative summary to investigators at the myocardial infarcn
tion confirmation core laboratory who were unaware of
treatment assignment .
Study end points . The primary
efficacy
end point was the
achievement of TIMI grade 3 flow at both 90 min and 18 to
36 h without death or reinfarction before the I1)- to 36-h
angiogram
. Patients were prespecified as "efficacy evalu-
able" if they underwent both angiogeams during study drug
therapy or met a primary efficacy end point before the 18- to
.'.6h angiogram. Prespecified secondary end points were the
incidence of death or reinfhrction, TIMI grade 3 flow, TIMI
grade 2 or 3 flow at 90 min and IS to 36 h and angiographic
reocetusico .
The primary safety end point was the occurrence of major
hemorrhage, defined as either an intracranial hemorrhage or
bleeding associated with a decrease in hemoglobin a5 gldl or
absolute decrease in hrratocrit at 15% (e .g., hematactit
decrease from 40% to 25%) (19) or anaphylaxis . Secondary
safety end points were the occurrence of hemorrhagic peri-
cardial tamponade or nonhemorrhagic stroke (19,20). All
patients who received the study drug were included in the
safety analyses.
Ltd point dub dean, Recurrent infarction occurring
within the lit IS h afterthe start of thromholytic therapy was
prospectively defined as recurrent ischemic pain at rest
lasting at least 30 min associated with new or recurrent ST
segment elevation a0.1 mV in at least two contiguous ECG
leads (19) . Criteria for cardiac enzymes were not included in
the definition of recurrent myocardial infarction during the
[at IS h because cardiac enzymes were still increasing from
the index myocardial infarction. After IS h, recurrent infarct-
thin was defined as recurrent ischemic pain lasting at least
30 min associated with either ECO or enzyme evidence of
reinfarctior,. The ECO evidence of reinferetion was defined
as either major (20 .03 ma) new Q waves in two or more
leads or new left bundle branch block in the absence of any
previous left bundle branch conduction defect. Enzyme
evidence of reinfaredon was defined as 1) total CK greater
than twice the upperlim(t of normal and increased by at least
25% over the previous value (qualitative creatine kinue, MB
fraction ICK-MB] was required to be positive [i.e., above
the upper limit of normal] when available, and CK-MB took
precedence over total CK); or 2) total CK less than twice the
upper limit of normal but exceeding the upper limit of normal
by at least 50% and increased by at least 50% over the
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Table A Primary Safety End Point
93spane earns all Mmdin. 4Jo4ne tiem as is Talk I .
Hemalalegle
dmdingn . The median activated partial
ilombeplaslin time values over time are shown in Table 5 .
At 24 h, the median activated partial thremhaplastin time in
the 0.05-mglhg per h hinsdindose group was similar to that of
heparin (63 s), whereas that for the 0 .2-mg/kg per h hirudin
dose was 15 s (p < 0 .001 across the four hirm in doses).
During We l st 12 h. 31,11% ofhepaaiin-treated patients bad an
activated patrol thronlboplastin time <60 a compared with
7 .1% of ihirttdht-treated patients (p < D .DDI). During the
study drug infusion period, after removal of the sheaths for
the second catheteriretion, the percent of patients who had
an activated partial thmmboplaslin lime that varied by <3D s
(similar to the target range of activated partial thromboplas-
tin lime) during the study drug infusion period was 36 .2% for
himdin.treated patients compared with 12.8% for hepmin-
treated patients (p = 0.004) gable 51. Using a range of 40 s,
55.0% of himdia4reated patients maintained a stable acti-
vated partial thromboplanlin time compared with 19 .1% of
heparin-treated patients (p = 0
.002) .
Discussion
Although tbmmbolytic therapy achieves early coronary
reperfusion. mauerous
procoagulant factors, the most im-
panam being Thrombin (24,25), me activated and can lead to
reoahsiai or rviofarcliun
. Became h11udle can Inhibit
dm botmd thrombin (26) End is bearer able to Inhibit duambin-
Table d. Results of Activated Pa i al Thrnnd xplaafin Tile Tests
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medialrd platelet actuation than heparin (1,15), its more
potent mithrombntic effects could be expected to improve
coronary patency and clinical outcome . The TIMI 5 trial
examined the efrecta or the specific thrombin inhibitor hiro-
din in patients with agate myocardial infarction treated with
t-PA and a sphin. in this pilot trial, himdin, compared with
heparin
. appeared
m
provide more stable anticoagulation,
decreased m7cclusion and greater infarctrelated artery pa-
lency at the later time point and, moat important, fewer
clinical events (dead[ or reinfaretion). With the insights
gained into the effects of hirudin on coronary reperfusion
and clinical outcome. this trial provides a strong rationale for
proceeding to larger vials to definitively evaluate the clinical
impact of hirudin after thrombolytic therapy .
TIMI grade 3 flaw. The achievement of TIM) grade 3
flow at either 90 min a 19 to 36 h has been shown by several
investigative groups to be associated with improved myocar-
dial salvage (27,28), a lower rate of reocclusion (29,30) .
improved left ventricular function (27 .31) and, most impor-
tant . improved survival (3,4,32,33). At the gamin angio'
gram, there was a nonsignifeaet rend for TIM[ grade 3 flow
favoring hirudin over heparin (64.8% vs . 57.1%). Hirudin
demonstrated a greater advantage in what might be termed
optimal thrombolysia, that is, the achievement of TIMI
grade 3 flow at both 90 min and 18 m 36 h (without death or
rednrarctlon), with 61 .6% of hintdin-treated patients having
this successful outcome compared with 49 .4% of heparin-
APTI - activated partial rrambophi0 ti- other abbenvidimls as in Titles 1 and
3 .
Mmhn APTT(s) (25Th, 71th pesnWks)
1rnldin
Tina Fpm
0.13 0(06 Iof 0.1 Snt tar 0.3 0.01 [of 0.6 40.2 ant As Dues Ikpam
.
0mdha 34(11.301 25(A31) 26(23.26) 25 (19.31)
33419, 211
6 k 7.4134. ON 95 (76. 1 l3) 77 (67,1321 101(93,123 t9(5a, 194)
12 11
7)165, 9ee 93 1], 1101 1618 .1107 107191.1191 76139, 133)
26 k 67(95,75) 19(16, 103) 76 (31 .131 85(75.1091
63(46, 75)
401 (57,9* 76167, 091 17 (61 .94) 91 (76. 1041
63151, I6)
72 k 04 (51,171 14(6l.109) 75 461 .94) 99(73.103) N (3172)
% k N(52,70 63 (63, 711
71
(67
.15
)
97(75.971 6s 171,17)
120 1, N 01,731 63 (41 .601 5707.571 97(93 .97)
73160, ml
ne,rah mote of AFrr -30, 40.5% 26.39E 27.7%
30e56 36253 1215E
Ph 9th mote of ART x401 09.7% 47A3E 40.4% 4041%
55
.0%
19.1%
E6rodia
H
.p
.dc
p Value'
11 .15114.6510 0.1110.1 bf 0.390.1W 0.6111111.21d An Dose
No. 5J N. % No . % r o, (6 No. %
t4o. %
to ety-Awe p, 57
34
79
51 156 86
M*- eP-- lnnordup 1 1 .9 1 2.9 0 0 0
0 2 1 .2
4 4
.7 0.09
Ma)alenortmeeataeisrrameIod .ik 6
11 .5
5.9 4 DA
15 VA
27
16.7 16 18.6 0.64
TaldnejahemOnIw6r 7
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Frequent monitoring will allow use of effective lntrmvenous
aoticoagulatlon in hospitals where the resources For close
dust= of intravenous heparin are not available .
Rebuttals at hiead -o dap to enhance. Although this trial
was a dose-ranging Dial of himdin, the absolute Rumber of
patients in each dose group vas small, thus letiting the
statistical powertocompare individual doses . Although each
of the four doses of hinrdin resulted in relatively similar
aogiogeaphic and clinical outcomes lIables 2 and 3), because
of the limiled sample size, a done response in efficacy , can
neither be Confirmed nor excluded Cram these data
. The four
doses did Lad to a dosc'lepcndell increase in the activated
partial thromlmpdnstin time, as well as a nonsignificant
increase in instrumented site hemorrhage at the highest
dose, the [enter finding demonstrating that this was most
likely the uanimal safe dose of hirudin . Conversely, spun
.
taneous hemorrhage was rare (196) in hirudiaueated pa-
tients
. indicating that in nonhstnlmented patients even the
highest dose could be expected to be well tolerated
.
Lhnhgllons of
Me
sandy. There are several potential
Ibnitations efthis study that should be considered . First, this
was an opeadabd pilot trial designed primarily to assess the
safety othiradin when given in cotgunction with !hroanbo-
lypic therapy. We did fad that hirudm was well tolerated and
were encouraged to find fltvorable trends for hirudin in
efficacy cod
points. However, these need to be cautioned in
hanger numbers of
patients . Second, the trial was a dose
escalation mkdy using four different doses of hirudin. Be .
cause findings were similar between the hirudin doses . for
the purposes ofcomparison with heparin, all doses of hirabn
were combined . For a definitive comparison with heperia, a
iingle dosing regimen at hirudin should be used. Third . a
major tad point of the Intel was to assess coronary potency
angiegophiwuy. It is possible that the end points of death .
relnfarclion and major hemorrhage could have been inPot-
entRd by the protocol design. Fourth, the imbalance in the
baseline charuetedstlea may have influenced the results . but
this would have favored heparin, not hirudin. Finally, al .
though the important rJlnical end point of death or minfmc-
tion wan algeificaatiy reduced in hirudin-treated patients, the
absolute number of events was small. reemphasizing the
need to test hirudin in a larger patient cohort .
Coadmism. In this pilot trial of patients with acute
myocardial Fdmction treated with front-loaded t.PA and
aspirin, hirudin appears to offer Several advantages over
hepagia Hirudin Improved the combination of early and
Mlsmlned TiNI grade 3 Now as well as coronary potency at
18 to 36 h and led to a moose stable clinical course, with
reduced ist-hospiml death or reinihredon
. Kindles provided a
muse stable activated partial thrumboplastin time without
adjustment of dose and was not associated with an increase
(n major hemonltagg .
Hirudlo is thus a promising adjunctive
agent to tbroelbolytla therapy, and a larger trial a warranted
to provide a definitive comparison between hirudin and
Aepnn .
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